• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 27, 2017

View Archived Issues

Expanding wisdom in rare disease diagnosis, Congenica adds $9.8M

LONDON – Clinical genomics specialist Congenica Ltd. has raised £8 million (US$9.8 million) in a series B round to advance the commercialization of its whole genome sequence rare diseases diagnosis system. Read More

Bench Press: BioWorld looks at translational medicine

Protein-protein interactions (PPIs), as a group, are both important for biological processes and hard to drug. One reason is that PPIs often occur via weak interactions at multiple sites, and blocking any one of those sites is not enough to inhibit the overall interaction between two proteins. Read More

In the clinic

Symic Bio Inc., of San Francisco, said it completed enrollment for the phase I/IIa SHIELD study of SB-030 in peripheral artery disease. Read More

Other news to note

Xynomic Pharmaceuticals Inc., of Cheyenne, Wyo., said it acquired exclusive worldwide rights to develop, manufacture and commercialize abexinostat, which the company describes as a potentially best-in-class HDAC inhibitor targeting hematological and solid tumors. Read More

Earnings

Biomarin Pharmaceutical Inc., of San Rafael, Calif., reported total revenues of $300 million for the fourth quarter, a 32 percent increase over the same period in 2015. Read More

Supreme Court reverses Federal Circuit in Promega patent spat

The Supreme Court of the U.S. has overturned a ruling by the Court of Appeals for the Federal Circuit in the case of Life Technologies v. Promega, but by some accounts, the outcome may do much more than declare that more than one component has to be involved in order to qualify as a “substantial component” of a purportedly infringing article. Read More

Market reshuffling: China’s revised NRDL to boost pharma sector

HONG KONG – China has added more than 300 new drugs to the National Reimbursement Drug List (NRDL) in its latest revision released Friday – the first since 2009. Read More

BTG backs combo use of immunotherapy, cancer interventional treatments

LONDON – BTG plc is to fund a program of research to explore how localized cryotherapy, radiotherapy and other image-guided cancer treatments could be used to sensitize so-called “cold” tumors that do not respond to checkpoint inhibitors or other forms of immunotherapy. Read More

Cempra success: Taksta takes ABSSSI to task in phase III trial

Cempra Inc. shares (NASDAQ:CEMP) rose 28.6 percent to $4.05 on Friday as the company reported that early clinical responses to its oral antibiotic, Taksta (fusidic acid), proved noninferior to those for Pfizer Inc.’s oral Zyvox (linezolid) during a phase III trial, meeting the primary endpoint. Read More

Idenix crown jewel crumbles as Merck takes $2.9 billion HCV write-down

Merck and Co. Inc. isn’t exactly ditching its hepatitis C virus (HCV) NS5B polymerase inhibitor, known as uprifosbuvir (MK-3682/3682B) – for now, at least. Enrollment continues in ongoing trials of uprifosbuvir – in development in triple- and double-combination HCV regimens, company spokeswoman Lainie Keller told BioWorld Today. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe